Inventor · disambiguated record
Elizabeth A. Buck
Also filed as: BUCK ELIZABETH · BUCK ELIZABETH A
9 granted patents·17 pending applications·54 citations·filing 1999–2021
85Inventor score
Files withBUCK ELIZABETH A8BLACK DIAMOND THERAPEUTICS INC5OSI PHARM INC3METASTAT INC2OSI PHARMACEUTICALS LLC2
Top patents by PatentIndex Score
26 records- 0192US7651687B2Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitorsOSI PHARM INC·Filed 2007·Granted Jan 26, 2010·33 cites·28 claims
- 0286US7939272B2Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitorsOSI PHARM INC·Filed 2008·Granted May 10, 2011·11 cites·10 claims
- 0385US11034672B1Tyrosine kinase inhibitor compositions, methods of making and methods of useBLACK DIAMOND THERAPEUTICS INC·Filed 2020·Granted Jun 15, 2021·2 cites·29 claims
- 0483US8114846B2Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitorsBUCK ELIZABETH A·Filed 2009·Granted Feb 14, 2012·4 cites·21 claims
- 0575US8575164B2Combination cancer therapyARNOLD LEE D·Filed 2008·Granted Nov 5, 2013·1 cites·14 claims
- 0666US8048621B2Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitorsOSI PHARMACEUTICALS LLC·Filed 2008·Granted Nov 1, 2011·1 cites·2 claims
- 0764US8586546B2Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitorsBUCK ELIZABETH A·Filed 2012·Granted Nov 19, 2013·1 cites·34 claims
- 0858US2022363666A1Tyrosine kinase inhibitor compositions, methods of making and methods of useBLACK DIAMOND THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0956US12435046B2Alkynyl quinazoline compoundsBLACK DIAMOND THERAPEUTICS INC·Filed 2020·Granted Oct 7, 2025·0 cites·20 claims
- 1053US2007286864A1Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitorsBUCK ELIZABETH A·Filed 2007·Application pending·0 cites
- 1151US2012101084A1Biological Markers Predictive of Anti-Cancer Response to Insulin-Like Growth Factor-1 Receptor Kinase InhibitorsHALEY JOHN D·Filed 2011·Application pending·0 cites
- 1250US2024075042A1Method of treating cancers with alkyne substituted quinazoline derivativesBLACK DIAMOND THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1345US2003157644A1Peptides and other small molecules derived from regions of interacting proteins and uses thereofSINAI SCHOOL MEDICINE·Filed 2002·Application pending·0 cites
- 1445US2009263397A1Combination anti-cancer therapyBUCK ELIZABETH A·Filed 2008·Application pending·0 cites
- 1544US2009274698A1Combination anti-cancer therapyBHAGWAT SHRIPAD·Filed 2008·Application pending·0 cites
- 1642US2013005733A1Combination anti-cancer therapyOSI PHARMACEUTICALS LLC·Filed 2011·Application pending·0 cites
- 1741US2010286155A1Adrenocortical carcinoma treatmentOSI PHARM INC·Filed 2010·Application pending·0 cites
- 1841US2022041613A1Tyrosine kinase inhibitor compositions, methods of making and methods of useBLACK DIAMOND THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1937US2012214830A1Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinomaBUCK ELIZABETH A·Filed 2012·Application pending·0 cites
- 2033US2004030134A1Process for preparation of integrin receptor antagonist intermediatesFiled 2001·Application pending·0 cites
- 2133US2011275644A1Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitorsBUCK ELIZABETH A·Filed 2011·Application pending·0 cites
- 2232US2012189641A1Combination anti-cancer therapyBUCK ELIZABETH A·Filed 2010·Application pending·0 cites
- 2332US2011217309A1Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitorsBUCK ELIZABETH A·Filed 2011·Application pending·0 cites
- 2429US2018271853A1Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variant IIIMETASTAT INC·Filed 2016·Application pending·0 cites
- 2527US2018117053A1The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VIMETASTAT INC·Filed 2016·Application pending·0 cites
- 2622US6555522B1Peptides and other small molecules derived from regions of interacting proteins and uses thereofSINAI SCHOOL MEDICINE·Filed 1999·Granted Apr 29, 2003·1 cites·23 claims
Join the waitlist — get patent alerts
Get an alert when Elizabeth A. Buck files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →